Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christiane Schaefer

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cell Communication and Signaling : CCS|May 20, 2018
The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signalingPhilipp Berning, Christiane Schaefer, Dagmar Clemens, et al.
Anti-Cancer Drugs|August 5, 2016
Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell linesAleksandra Pettke, Marc Hotfilder, Dagmar Clemens, et al.
Plos One|February 1, 2018
Target discovery screens using pooled shRNA libraries and next-generation sequencing: A model workflow and analytical algorithmChristiane Schaefer, Nikhil Mallela, Jochen Seggewiß, et al.
Molecular Oncology|January 8, 2016
Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic diseaseJenny Potratz, Amelie Tillmanns, Philipp Berning, et al.
Cancers|April 11, 2020
The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing SarcomaPhilipp Berning, Carolin Hennemann, Claudia Tulotta, et al.
Cancers|December 11, 2022
Ewing Sarcoma as Secondary Malignant Neoplasm-Epidemiological and Clinical Analysis of an International Trial RegistryStefan K Zöllner, Katja L Kauertz, Isabelle Kaiser, et al.
Scientific Reports|March 28, 2026
Elimusertib enhances cytotoxic effects of conventional chemotherapy and sensitizes to radiation in preclinical Ewing sarcoma modelsLeonhard Koch, Maximilian Kerkhoff, Maximilian Bretschneider, et al.
Bioengineering (Basel, Switzerland)|April 28, 2023
Evaluation of the Effect of Photodynamic Therapy on CAM-Grown SarcomasMaximilian Kerkhoff, Susanne Grunewald, Christiane Schaefer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2020
Correction to: Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from <sup>18</sup>F-FDG-PET/CT and circulating tumor DNAChristian Schmidkonz, Manuela Krumbholz, Armin Atzinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 20, 2019
Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from <sup>18</sup>F-FDG-PET/CT and circulating tumor DNAChristian Schmidkonz, Manuela Krumbholz, Armin Atzinger, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cell Communication and Signaling : CCS|May 20, 2018
The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signalingPhilipp Berning, Christiane Schaefer, Dagmar Clemens, et al.
Anti-Cancer Drugs|August 5, 2016
Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell linesAleksandra Pettke, Marc Hotfilder, Dagmar Clemens, et al.
Plos One|February 1, 2018
Target discovery screens using pooled shRNA libraries and next-generation sequencing: A model workflow and analytical algorithmChristiane Schaefer, Nikhil Mallela, Jochen Seggewiß, et al.
Molecular Oncology|January 8, 2016
Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic diseaseJenny Potratz, Amelie Tillmanns, Philipp Berning, et al.
Cancers|April 11, 2020
The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing SarcomaPhilipp Berning, Carolin Hennemann, Claudia Tulotta, et al.
Cancers|December 11, 2022
Ewing Sarcoma as Secondary Malignant Neoplasm-Epidemiological and Clinical Analysis of an International Trial RegistryStefan K Zöllner, Katja L Kauertz, Isabelle Kaiser, et al.
Scientific Reports|March 28, 2026
Elimusertib enhances cytotoxic effects of conventional chemotherapy and sensitizes to radiation in preclinical Ewing sarcoma modelsLeonhard Koch, Maximilian Kerkhoff, Maximilian Bretschneider, et al.
Bioengineering (Basel, Switzerland)|April 28, 2023
Evaluation of the Effect of Photodynamic Therapy on CAM-Grown SarcomasMaximilian Kerkhoff, Susanne Grunewald, Christiane Schaefer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2020
Correction to: Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from <sup>18</sup>F-FDG-PET/CT and circulating tumor DNAChristian Schmidkonz, Manuela Krumbholz, Armin Atzinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 20, 2019
Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from <sup>18</sup>F-FDG-PET/CT and circulating tumor DNAChristian Schmidkonz, Manuela Krumbholz, Armin Atzinger, et al.
Pageof 2